Alcobra Ltd. to Participate in Piper Jaffray 27th Annual Healthcare Conference

TEL AVIV, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference.

Piper Jaffray 27th Annual Healthcare Conference
Panel Title: "Underdiscovered NeuroInnovators"
Date: Wednesday, December 2
Time: 10:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Tomer Berkovitz, CFO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.